Lilleri Daniele, Fornara Chiara, Chiesa Antonella, Caldera Daniela, Alessandrino Emilio Paolo, Gerna Giuseppe
Servizio di Virologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
Haematologica. 2008 Feb;93(2):248-56. doi: 10.3324/haematol.11912.
Human cytomegalovirus infection is the most frequent viral complication in patients undergoing hematopoietic stem cell transplantation. We investigated the development of human cytomegalovirus-specific T cells in adult recipients of hematopoietic stem cell transplants.
From May 2003 through October 2006 a total of 45 patients were monitored for human cytomegalovirus-specific T-cell reconstitution. Human cytomegalovirus-infected autologous dendritic cells were used as a stimulus to detect interferon-gamma-producing human cytomegalovirus-specific CD8(+) and CD4(+) T cells during the first year after transplantation. Interleukin-2 production by specific T cells was also determined.
Human cytomegalovirus infection was detected in the blood of 39/45 patients at a median of 29 days after transplantation. Human cytomegalovirus-specific T-cell reconstitution followed reactivation of latent human cytomegalovirus infection at a median time of about 2 months after transplantation. Only donor human cytomegalovirus-seronegativity and bone marrow as a stem cell source were found to delay specific T-cell reconstitution significantly. Levels of three CD8(+) and one CD4(+) human cytomegalovirus-specific T-cells/microL blood had a positive predictive value of around 80% for identifying patients able to control human cytomegalovirus infection spontaneously. Five patients who received high doses of steroids for treatment of graft-versus-host disease developed human cytomegalovirus infection requiring pre-emptive treatment despite high levels of interferon-gamma-producing T cells in response to human cytomegalovirus. Specific interleukin-2 production was not detected in patients with human cytomegalovirus infection requiring treatment, while 90% of patients who spontaneously controlled human cytomegalovirus infection had T cells that produced interleukin-2 and interferon-gamma.
Pre-transplant human cytomegalovirus infection of the recipient is a major factor driving human cytomegalovirus-specific immune reconstitution. Control of human cytomegalovirus infection likely requires the presence of both interferon-gamma and interleukin-2 producing T cells. Corticosteroid treatment may favor active viral replication even in patients with specific T cells.
人类巨细胞病毒感染是造血干细胞移植患者中最常见的病毒并发症。我们研究了造血干细胞移植成年受者中人类巨细胞病毒特异性T细胞的发育情况。
2003年5月至2006年10月,共监测了45例患者的人类巨细胞病毒特异性T细胞重建情况。使用人类巨细胞病毒感染的自体树突状细胞作为刺激物,在移植后的第一年检测产生干扰素-γ的人类巨细胞病毒特异性CD8(+)和CD4(+) T细胞。还测定了特异性T细胞产生白细胞介素-2的情况。
45例患者中有39例在移植后中位29天的血液中检测到人类巨细胞病毒感染。人类巨细胞病毒特异性T细胞重建在潜伏性人类巨细胞病毒感染重新激活后出现,中位时间约为移植后2个月。仅发现供体人类巨细胞病毒血清阴性和作为干细胞来源的骨髓会显著延迟特异性T细胞重建。每微升血液中三种CD8(+)和一种CD4(+)人类巨细胞病毒特异性T细胞的水平对于识别能够自发控制人类巨细胞病毒感染的患者具有约80%的阳性预测价值。5例因移植物抗宿主病接受高剂量类固醇治疗的患者发生了人类巨细胞病毒感染,尽管对人类巨细胞病毒有高水平的产生干扰素-γ的T细胞,但仍需要进行抢先治疗。在需要治疗的人类巨细胞病毒感染患者中未检测到特异性白细胞介素-2的产生,而90%自发控制人类巨细胞病毒感染的患者具有产生白细胞介素-2和干扰素-γ的T细胞。
受者移植前的人类巨细胞病毒感染是驱动人类巨细胞病毒特异性免疫重建的主要因素。控制人类巨细胞病毒感染可能需要同时存在产生干扰素-γ和白细胞介素-2的T细胞。即使在有特异性T细胞的患者中,皮质类固醇治疗也可能有利于病毒的活跃复制。